Stacy E Croteau

List of Publications by Year
in descending order

61 papers	1,213 citations	471371 17 h-index	395590 33 g-index
62 all docs	62 docs citations	62 times ranked	1343 citing authors

#	Article	IF	Citations
1	A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Childrenâ€™s Hospital-Acquired Thrombosis Consortium. Pediatric Critical Care Medicine, 2022, 23, e1-e9.	0.2	12
2	Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. Journal of Thrombosis and Haemostasis, 2022, 20, 133-137.	1.9	6
3	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) â€“ Unmet needs remain. Haemophilia, 2022, 28, 453-461.	1.0	5
4	Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 449-460.	0.5	5
5	Kaposiform Lymphangiomatosis. American Journal of Surgical Pathology, 2022, 46, 963-976.	2.1	11
6	Hemophilia A/B. Hematology/Oncology Clinics of North America, 2022, 36, 797-812.	0.9	0
7	<scp>2021</scp> clinical trials update: Innovations in hemophilia therapy. American Journal of Hematology, 2021, 96, 128-144.	2.0	37
8	Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Reviews, 2021, 47, 100759.	2.8	40
9	Natural history study of factor IX deficiency with focus on treatment and complications (Bâ€Natural). Haemophilia, 2021, 27, 49-59.	1.0	6
10	Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. Haemophilia, 2021, 27, e270-e273.	1.0	2
11	Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. Journal of Pediatrics, 2021, 228, 252-259.e1.	0.9	23
12	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia, 2021, 27, 211-220.	1.0	3
13	Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 316-326.	0.5	13
14	Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. Journal of Thrombosis and Haemostasis, 2021, 19, 976-982.	1.9	3
15	The Bâ€Natural studyâ€”The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia, 2021, 27, 802-813.	1.0	11
16	Phage display broadly identifies inhibitorâ€reactive regions in von Willebrand factor. Journal of Thrombosis and Haemostasis, 2021, 19, 2702-2709.	1.9	4
17	Assessment of TRM-201 (Rofecoxib) Efficacy and Safety for Chronic Pain in Hemophilic Arthropathy: The Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy (RESET-HA), a Randomized, Double-Blind Placebo-Controlled Phase III Clinical Trial. Blood, 2021, 138, 4243-4243.	0.6	0
18	Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study. Pediatric Blood and Cancer, 2020, 67, e28004.	0.8	5

#	Article	IF	Citations
19	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (AdynovateÂ®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics, 2020, 59, 245-256.	1.6	18
20	Clinical application of Web Accessible Population Pharmacokinetic Serviceâ€"Hemophilia (WAPPSâ€Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia, 2020, 26, 56-63.	1.0	7
21	The impact of extended halfâ€life factor concentrates on prophylaxis for severe hemophilia in the United States. American Journal of Hematology, 2020, 95, 960-965.	2.0	19
22	Low von Willebrand factor in pediatric patients: Retrospective analysis of 293 cases informs diagnostic and therapeutic decision making. Pediatric Blood and Cancer, 2020, 67, e28497.	0.8	2
23	Spontaneous bleeding and poor bleeding response with extended halfâ€life factor IX products: A survey of select US haemophilia treatment centres. Haemophilia, 2020, 26, e128-e129.	1.0	19
24	Pharmacokineticâ€tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 326-333.	1.0	13
25	An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. Journal of Inherited Metabolic Disease, 2020, 43, 880-890.	1.7	14
26	First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Î'. Blood, 2020, 136, 8-8.	0.6	4
27	Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTIONâ€TOâ€HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers. Haemophilia, 2020, 26, 3-19.	1.0	3
28	Incidence of Pulmonary Embolus after Catheter Removal in Children with Central Venous Catheter Related Venous Thromboembolism: A Report from the CHAT Consortium. Blood, 2020, 136, 5-6.	0.6	1
29	Assessing Patient and Provider Perspectives, Clinical Practice, Behaviors, and Knowledge on Hemophilia A Care. Blood, 2020, 136, 24-25.	0.6	0
30	Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. Blood, 2020, 136, 2-3.	0.6	0
31	Regional variation and cost implications of prescribed extended halfâ€life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia, 2019, 25, 668-675.	1.0	38
32	Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia, 2019, 25, e126-e129.	1.0	0
33	Bioengineering hemophilia Aâ€"specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Advances, 2019, 3, 4166-4176.	2.5	15
34	Diagnostic and Therapeutic Decision Making in Pediatric Patients with Low Von Willebrand Factor. Blood, 2019, 134, 2414-2414.	0.6	2
35	Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers. Blood, 2019, 134, 2407-2407.	0.6	6
36	Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A. Blood, 2019, 134, 3637-3637.	0.6	1

#	Article	IF	Citations
37	The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning. Blood, 2019, 134, 635-635.	0.6	0
38	Assessing Venous Thromboembolism Risk in Critically Ill Children: A Report from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium. Blood, 2019, 134, 1150-1150.	0.6	0
39	The spectrum of bleeding in women and girls with haemophilia B. Haemophilia, 2018, 24, 180-185.	1.0	15
40	Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 607-614.	1.0	13
41	Evolving Complexity in Hemophilia Management. Pediatric Clinics of North America, 2018, 65, 407-425.	0.9	10
42	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	1.0	50
43	Shifting landscape of hemophilia therapy: Implications for current clinical laboratory coagulation assays. American Journal of Hematology, 2018, 93, 1082-1090.	2.0	19
44	Thrombotic Events with NovoSevenÂ® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs. Blood, 2018, 132, 1203-1203.	0.6	1
45	A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds. Blood, 2018, 132, 487-487.	0.6	41
46	Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates. Blood, 2018, 132, 2467-2467.	0.6	0
47	Recombinant porcine factor <scp>VIII</scp> for highâ€risk surgery in paediatric congenital haemophilia A with highâ€titre inhibitor. Haemophilia, 2017, 23, e93-e98.	1.0	17
48	Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Frontiers in Pediatrics, 2017, 5, 68.	0.9	53
49	Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood, 2017, 130, 89-89.	0.6	41
50	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatric Blood and Cancer, 2016, 63, 1822-1828.	0.8	8
51	2017 Clinical trials update: Innovations in hemophilia therapy. American Journal of Hematology, 2016, 91, 1252-1260.	2.0	82
52	Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence:HEMO-Milestones Toolin a Comprehensive Hemophilia Clinic Setting. Pediatric Blood and Cancer, 2016, 63, 499-503.	0.8	6
53	The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma. Seminars in Cutaneous Medicine and Surgery, 2016, 35, 147-152.	1.6	28
54	Transition considerations for extended halfâ€life factor products. Haemophilia, 2015, 21, 285-288.	1.0	17

#	Article	IF	Citations
55	Author's response: â€˜Transition considerations for extended half-life factor productsâ€™. Haemophilia, 2015, 21, e454-e455.	1.0	2
56	Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centreâ€based pharmacy hit the mark?. Haemophilia, 2015, 21, 190-195.	1.0	2
57	Kaposiform Lymphangiomatosis: A Distinct Aggressive Lymphatic Anomaly. Journal of Pediatrics, 2014, 164, 383-388.	0.9	127
58	Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients.. Journal of Clinical Oncology, 2014, 32, 222-222.	0.8	0
59	Novel dominant Î²â€thalassemia: Hb Bostonâ€Kuwait [Codon 139/140(+T)]. Pediatric Blood and Cancer, 2013, 60, E131-4.	0.8	10
60	Kaposiform Hemangioendothelioma: Atypical Features and Risks of Kasabach-Merritt Phenomenon in 107 Referrals. Journal of Pediatrics, 2013, 162, 142-147.	0.9	314
61	Resolving bony abnormality evolves to diffuse large Bâ€cell lymphoma. Pediatric Blood and Cancer, 2013, 60, E113-5.	0.8	1